| Clinicopathologic and molecular characteristics of mesonephric adenocarcinoma arising from the uterine body K Na, HS Kim The American journal of surgical pathology 43 (1), 12-25, 2019 | 115 | 2019 |
| Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer HS Kim, G Yoon, JY Ryu, YJ Cho, JJ Choi, YY Lee, TJ Kim, CH Choi, ... Oncotarget 6 (29), 26746, 2015 | 73 | 2015 |
| External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous … JY Lee, YS Chung, K Na, HM Kim, CK Park, EJ Nam, S Kim, SW Kim, ... Journal of gynecologic oncology 28 (6), 2017 | 66 | 2017 |
| Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases K Na, HS Kim, HS Shim, JH Chang, SG Kang, SH Kim Journal of Neuro-Oncology 142, 445-454, 2019 | 53 | 2019 |
| Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix E Park, SW Kim, S Kim, HS Kim, JY Lee, YT Kim, NH Cho Modern Pathology 34 (3), 637-646, 2021 | 47 | 2021 |
| Clinicopathologic correlation of beclin-1 expression in pancreatic ductal adenocarcinoma HS Kim, SH Lee, SI Do, SJ Lim, YK Park, YW Kim Pathology-Research and Practice 207 (4), 247-252, 2011 | 46 | 2011 |
| Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer HS Kim, JY Kim, YJ Lee, SH Kim, JY Lee, EJ Nam, S Kim, SW Kim, ... Gynecologic Oncology 151 (3), 414-421, 2018 | 45 | 2018 |
| Loss of Raf-1 kinase inhibitory protein in pancreatic ductal adenocarcinoma HS Kim, GY Kim, SJ Lim, YW Kim Pathology 42 (7), 655-660, 2010 | 44 | 2010 |
| Stromal CD10 expression and relationship to the E‐cadherin/β‐catenin complex in breast carcinoma HS Kim, GY Kim, YW Kim, YK Park, JY Song, SJ Lim Histopathology 56 (6), 708-719, 2010 | 43 | 2010 |
| TP53 mutation status of tubo-ovarian and peritoneal high-grade serous carcinoma with a wild-type p53 immunostaining pattern K Na, JY Sung, HS Kim Anticancer research 37 (12), 6697-6703, 2017 | 40 | 2017 |
| Increased brahma-related gene 1 expression predicts distant metastasis and shorter survival in patients with invasive ductal carcinoma of the breast SI Do, G Yoon, HS Kim, K Kim, H Lee, IG Do, DH Kim, SW Chae, JH Sohn Anticancer research 36 (9), 4873-4882, 2016 | 38 | 2016 |
| Stromal p16 expression is significantly increased in endometrial carcinoma G Yoon, CW Koh, N Yoon, JY Kim, HS Kim Oncotarget 8 (3), 4826, 2017 | 37 | 2017 |
| Anti‐angiogenic factor endostatin in osteosarcoma HSOO KIM, SJIG LIM, YKOO PARK Apmis 117 (10), 716-723, 2009 | 37 | 2009 |
| A giant peritoneal loose body HS Kim, JY Sung, WS Park, YW Kim Korean Journal of Pathology 47 (4), 378, 2013 | 34 | 2013 |
| Stromal p16 expression is significantly increased in malignant ovarian neoplasms N Yoon, G Yoon, CK Park, HS Kim Oncotarget 7 (40), 64665, 2016 | 33 | 2016 |
| Reduced expression of Raf-1 kinase inhibitory protein predicts regional lymph node metastasis and shorter survival in esophageal squamous cell carcinoma HS Kim, KY Won, GY Kim, SC Kim, YK Park, YW Kim Pathology-Research and Practice 208 (5), 292-299, 2012 | 33 | 2012 |
| Carcinosarcoma of the pancreas: a unique case with emphasis on metaplastic transformation and the presence of undifferentiated pleomorphic high-grade sarcoma HS Kim, SH Joo, DM Yang, SH Lee, SH Choi, SJ Lim J Gastrointestin Liver Dis 20 (2), 197-200, 2011 | 33 | 2011 |
| Giant superficial angiomyxoma of the vulva: a case report and review of the literature HS Kim, GY Kim, SJ Lim, KD Ki, HC Kim Journal of cutaneous pathology 37 (6), 672-677, 2010 | 32 | 2010 |
| Raf-1 kinase inhibitory protein expression in thyroid carcinomas HS Kim, GY Kim, SJ Lim, YW Kim Endocrine pathology 21, 253-257, 2010 | 31 | 2010 |
| CTNNB1 mutations in ovarian microcystic stromal tumors: identification of a novel deletion mutation and the use of pyrosequencing to identify reported point mutation K Na, EK Kim, W Jang, HS Kim Anticancer Research 37 (6), 3249-3258, 2017 | 30 | 2017 |
